GENERAL CLINICAL RESEARCH CENTER
全科临床研究中心
基本信息
- 批准号:8356650
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-12-01 至 2011-05-31
- 项目状态:已结题
- 来源:
- 关键词:Alcohol dependenceAtherosclerosisAutoimmunityBehaviorChronic Kidney FailureClinical ResearchClinical SciencesComplexCytologyDataDiabetes MellitusDiabetic NephropathyDisciplineDiseaseEnvironmentEquipmentFacultyFibroblastsFundingGeneticGenomicsGenotypeGrantHealthHuman ResourcesInfectionInflammatory Bowel DiseasesInpatientsInstitutionJointsKidney DiseasesMedical centerMental DepressionMethamphetamineMinorityMolecularMonitorNational Center for Research ResourcesOsteoporosisOutpatientsPediatricsPerinatalPhenotypePositioning AttributePrincipal InvestigatorProteomicsProtocols documentationReproductionResearchResearch InfrastructureResearch PersonnelResearch TrainingResourcesRunningSafetySampling StudiesSourceStudentsToxicologyTrainingTraining ActivityTranslational ResearchUnited States National Institutes of HealthVisitWorkbasecostmalemetabolic abnormality assessmentnutritionparent grantphase 1 studyreproductiveskeletal dysplasia
项目摘要
This subproject is one of many research subprojects utilizing the resources
provided by a Center grant funded by NIH/NCRR. Primary support for the subproject
and the subproject's principal investigator may have been provided by other sources,
including other NIH sources. The Total Cost listed for the subproject likely
represents the estimated amount of Center infrastructure utilized by the subproject,
not direct funding provided by the NCRR grant to the subproject or subproject staff.
The GCRC at Harbor-UCLA Medical Center and the satellite GCRC at Cedars-Sinai Medical Center are
applying for continued funding of the GCRCs for 5 years (12/01/2006 to 11/30/2011). The Harbor-UCLA
GCRC is requesting support for an inpatient unit (800 days), outpatient facilities (9,000 visits), a perinatal/
pediatrics unit (7,000 hrs). The Cedars GCRC satellite is seeking continued support for an outpatient unit, a
complex genotype-phenotype core and a perinatal unit working closely with its Harbor counterpart. The
current application contains 93 protocols from Harbor and 95 from Cedars, each with Data Safety Monitoring
plans. The GCRCs are requesting support for a new joint Clinjcal Transcriptional Genomics, Proteomics
and Molecular Cytology core with 47 protocols utilizing this proposed core. Reviewed and given an excellent
score, this core was not funded in 2004 because of NCRR's budgetary constraints. Similar to the GCRC
parent grant, the core's strengths include outstanding qualifications of the investigators-core directors, the
capability to provide a training environment, and a substantial number of investigators and protocols from a
broad range of disciplines. Our institutions have generously provided major equipment in the past 2 years
and provided interim support for personnel to run the proposed core. Our presented proto-cols demonstrate
the broad base of our well-funded investigators with diverse research including emerging infections, chronic
kidney disease, fibroblasts in autoimmunity, male reproduction, neurotrauma, skeletal dysplasia and
inflammatory bowel disease. We support high-volume outpatient studies (SELECT, Nutrition and Kidney
Disease), high-intensity inpatient studies (Phase I safety and pharmacokihetics studies, metabolic and
multiple sample studies), perinatal research (reproductive toxicology, methamphetamine exposed babies),
behavior studies (depression, alcohol dependence), and genetics of common diseases (diabetes, diabetic
nephropathy, osteoporosis, atherosclerosis). The GCRCs are the focus of clinical research training in their
respective institutions reaching out to junior faculty, fellows, and minority graduate and undergraduate
students, and our training activity is ranked "outstanding" in our last review. The GCRCs are positioned to be
part of Centers for Clinical and Translational Sciences in our institutions following the NIH Roadmap to reengineer
the clinical research enterprise of academic health centers in the nation.
这个子项目是许多利用资源的研究子项目之一
由NIH/NCRR资助的中心拨款提供。子项目的主要支持
而子项目的主要调查员可能是由其他来源提供的,
包括其它NIH来源。 列出的子项目总成本可能
代表子项目使用的中心基础设施的估计数量,
而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。
位于Harbor-UCLA医疗中心的GCRC和位于Cedars-Sinai医疗中心的卫星GCRC
申请继续资助GCRC五年(12/01/2006至11/30/2011)。加州大学洛杉矶分校
儿童权利中心请求支助一个住院部(800天)、门诊设施(9 000次就诊)、一个围产期/产期护理中心(10 000天)和一个儿童保健中心(10 000天)。
儿科股(7 000小时)。雪松GCRC卫星正在寻求继续支持门诊单位,
复杂的基因型-表型核心和围产期单位密切合作,其港口对应。的
当前的应用程序包含来自Harbor的93个协议和来自Cedars的95个协议,每个协议都具有数据安全监控功能
布局GCRC正在请求支持新的联合临床转录基因组学,蛋白质组学
和分子细胞学核心与47个协议利用这个建议的核心。审查并给出了一个很好的
由于国家难民救济委员会的预算限制,2004年没有为这一核心项目提供资金。类似于GCRC
母公司补助金,核心的优势包括优秀的资格认证人员-核心董事,
有能力提供培训环境,并有大量调查人员和来自
广泛的学科。我们的机构在过去两年里慷慨地提供了主要设备
并为管理拟议核心的人员提供临时支助。我们提出的协议表明
我们资金充足的调查人员的广泛基础,他们进行了各种研究,包括新出现的感染、慢性
肾脏疾病、自身免疫中的成纤维细胞、男性生殖、神经创伤、骨骼发育不良和
炎症性肠病我们支持大量门诊研究(SELECT、营养和肾脏
疾病)、高强度住院研究(I期安全性和代谢动力学研究、代谢和
多样本研究),围产期研究(生殖毒理学,接触甲基苯丙胺的婴儿),
行为研究(抑郁症,酒精依赖)和常见疾病的遗传学(糖尿病,糖尿病
肾病、骨质疏松症、动脉粥样硬化)。GCRC是临床研究培训的重点,
各机构向初级教师、研究员和少数民族研究生和本科生伸出援手
我们的培训活动在上次评审中被评为“优秀”。GCRC的定位是
我们机构的临床和转化科学中心的一部分,遵循NIH路线图,
全国学术健康中心的临床研究企业。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHRISTINA C. WANG其他文献
CHRISTINA C. WANG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHRISTINA C. WANG', 18)}}的其他基金
HYPOPITUITARISM IN RETIRED PROFESSIONAL FOOTBALL PLAYERS
退役职业足球运动员的垂体功能低下
- 批准号:
8174513 - 财政年份:2009
- 资助金额:
-- - 项目类别:
CLINICAL TRIAL: TRIAL TO EVALUATE THE EFFECTIVENESS AND SAFETY OF DIFF DOSES OF
临床试验:评估不同剂量的有效性和安全性的试验
- 批准号:
8174509 - 财政年份:2009
- 资助金额:
-- - 项目类别:
CLINICAL TRIAL: A MULTIPLE DOSE, PHARMACOKINETIC STUDY
临床试验:多剂量药代动力学研究
- 批准号:
8174500 - 财政年份:2009
- 资助金额:
-- - 项目类别:
A MULTICENTER, RANDOMIZED COMPARATOR TRIAL OF THE SAFETY AND SPERM AND GONADOTRO
安全性与精子和促性腺激素的多中心、随机比较试验
- 批准号:
8174515 - 财政年份:2009
- 资助金额:
-- - 项目类别:
DEVELOPMENT AND VALIDATION OF STEROID AND OTHER ASSAYS BY LIQUID CHROMATOGRAPHY
类固醇和其他液相色谱分析方法的开发和验证
- 批准号:
8174528 - 财政年份:2009
- 资助金额:
-- - 项目类别:
相似海外基金
Autoimmunity as a Mechanism for Atherosclerosis in COPD
自身免疫作为慢性阻塞性肺病动脉粥样硬化的机制
- 批准号:
8860899 - 财政年份:2015
- 资助金额:
-- - 项目类别:
Cross-Regulation of Atherosclerosis and Autoimmunity
动脉粥样硬化和自身免疫的交叉调节
- 批准号:
8761633 - 财政年份:2014
- 资助金额:
-- - 项目类别:
Cross-Regulation of Atherosclerosis and Autoimmunity
动脉粥样硬化和自身免疫的交叉调节
- 批准号:
8891486 - 财政年份:2014
- 资助金额:
-- - 项目类别:
Role of iNKT Cells in Autoimmunity and Atherosclerosis
iNKT 细胞在自身免疫和动脉粥样硬化中的作用
- 批准号:
7840704 - 财政年份:2009
- 资助金额:
-- - 项目类别:
Role of iNKT Cells in Autoimmunity and Atherosclerosis
iNKT 细胞在自身免疫和动脉粥样硬化中的作用
- 批准号:
7298454 - 财政年份:2007
- 资助金额:
-- - 项目类别:
Role of iNKT Cells in Autoimmunity and Atherosclerosis
iNKT 细胞在自身免疫和动脉粥样硬化中的作用
- 批准号:
7900350 - 财政年份:2007
- 资助金额:
-- - 项目类别:
Role of iNKT Cells in Autoimmunity and Atherosclerosis
iNKT 细胞在自身免疫和动脉粥样硬化中的作用
- 批准号:
7500836 - 财政年份:2007
- 资助金额:
-- - 项目类别:
Role of iNKT Cells in Autoimmunity and Atherosclerosis
iNKT 细胞在自身免疫和动脉粥样硬化中的作用
- 批准号:
8111924 - 财政年份:2007
- 资助金额:
-- - 项目类别: